KEJIDALONG BIOTECHNOLOGY CO., LTD. – Trademark Portfolio

Entity Type: 16

KEJIDALONG BIOTECHNOLOGY CO., LTD. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 3 Nice Classification classes. The owner is based in BEIJING.

NO. 27, LIFE SCIENCE PARK ROAD

CHANGPING DIST.

BEIJING 102206 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CROPEDIT
CROPEDIT
Abandoned 2019
CROPEDIT
CROPEDIT
Abandoned 2019

Trademark Classifications

KEJIDALONG BIOTECHNOLOGY CO., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (2 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

31
Natural Agricultural Products (2 filings)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does KEJIDALONG BIOTECHNOLOGY CO., LTD. have?

KEJIDALONG BIOTECHNOLOGY CO., LTD. has 2 U.S. trademarks filed with the USPTO.

What trademark classes does KEJIDALONG BIOTECHNOLOGY CO., LTD. file in?

KEJIDALONG BIOTECHNOLOGY CO., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 31 (Natural Agricultural Products), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What is KEJIDALONG BIOTECHNOLOGY CO., LTD.'s trademark registration success rate?

KEJIDALONG BIOTECHNOLOGY CO., LTD. has a 0% trademark registration rate, with 0 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.